P-33 COMBINATION OF FIB-4 SCORE AND D-DIMER TO PREDICT OUTCOME IN HOSPITALIZED COVID-19 PATIENTS

No Identifying risk factors for poor outcomes is crucial for defining treatment strategies and allocating resources in COVID-19. The Fibrose-4 score (FIB-4) and D-dimer (DD) have emerged as prognostic markers; however, precise cutoff points and their combined use remain unstudied. Objectives: This study aimed to compare the individual and combined performance of FIB-4 and DD in predicting outcomes among COVID-19 patients. Materials and Methods: From March to December/2020, hospitalized COVID-19 patients were evaluated regarding laboratory admission tests, chest CT scan, gender, age, lung involvement, ICU admission, hemodialysis, mechanical ventilation, and mortality. Optimal FIB-4 and DD cutoffs to predict in-hospital mortality, aiming to maximize sensitivity and specificity, were established. A sequential diagnostic strategy using both markers was subsequently evaluated. Results and Discussion: Among 518 patients (61±16 years, 64% men), the in-hospital mortality rate was 18%. FIB-4 showed superior performance in predicting mortality compared to DD (AUROC 0.76 vs . 0.65, p=0.003) and was chosen as the first step in sequential analysis. Mortality was higher in patients with FIB-4≥1.76 vs. FIB-4<1.76 (26% vs. 5%, p<0.001) and DD≥2000 ng/mL FEU vs. DD<2000 ng/mL FEU (38% vs. 16%, p<0.001). FIB-4 was used as a screening test, with a cutoff point of 1.76 (90% sensitivity in ROC curve analysis), followed by DD measurement with a cutoff value of 2000 ng/mL FEU (specificity of 90%). Through this approach, a subgroup of patients with a higher mortality rate was identified, compared to the use of FIB-4 alone (48% vs. 26%, p<0.001), missing the identification of only 4.7% of deaths. The sequential use of FIB-4 and DD represents a comprehensive strategy to identify high-risk COVID-19 patients at hospital admission, potentially minimizing unnecessary DD assessments in patients initially classified by FIB-4 as low-risk for adverse outcomes.

Authors

Institutions

Publication Details

Journal
Annals of Hepatology
Published
2024-12-01
DOI
https://doi.org/10.1016/j.aohep.2024.101647
Primary Topic
COVID-19 Clinical Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P-33 COMBINATION OF FIB-4 SCORE AND D-DIMER TO PREDICT OUTCOME IN HOSPITALIZED COVID-19 PATIENTS

Thainá Rodrigues de Melo, Robert P. Mello, Ronir Raggio Luiz, Maria Chiara Chindamo et al.
Annals of Hepatology
COVID-19 Clinical Research Studies
article

P-33 COMBINATION OF FIB-4 SCORE AND D-DIMER TO PREDICT OUTCOME IN HOSPITALIZED COVID-19 PATIENTS

Thainá Rodrigues de Melo, Robert P. Mello, Ronir Raggio Luiz, Maria Chiara Chindamo, José Gomes, Fernanda Pozzobon Manhães, Maria Paula Cunha Fontes Raymundo
article en

Abstract

No Identifying risk factors for poor outcomes is crucial for defining treatment strategies and allocating resources in COVID-19. The Fibrose-4 score (FIB-4) and D-dimer (DD) have emerged as prognostic markers; however, precise cutoff points and their combined use remain unstudied. Objectives: This study aimed to compare the individual and combined performance of FIB-4 and DD in predicting outcomes among COVID-19 patients. Materials and Methods: From March to December/2020, hospitalized COVID-19 patients were evaluated regarding laboratory admission tests, chest CT scan, gender, age, lung involvement, ICU admission, hemodialysis, mechanical ventilation, and mortality. Optimal FIB-4 and DD cutoffs to predict in-hospital mortality, aiming to maximize sensitivity and specificity, were established. A sequential diagnostic strategy using both markers was subsequently evaluated. Results and Discussion: Among 518 patients (61±16 years, 64% men), the in-hospital mortality rate was 18%. FIB-4 showed superior performance in predicting mortality compared to DD (AUROC 0.76 vs . 0.65, p=0.003) and was chosen as the first step in sequential analysis. Mortality was higher in patients with FIB-4≥1.76 vs. FIB-4<1.76 (26% vs. 5%, p<0.001) and DD≥2000 ng/mL FEU vs. DD<2000 ng/mL FEU (38% vs. 16%, p<0.001). FIB-4 was used as a screening test, with a cutoff point of 1.76 (90% sensitivity in ROC curve analysis), followed by DD measurement with a cutoff value of 2000 ng/mL FEU (specificity of 90%). Through this approach, a subgroup of patients with a higher mortality rate was identified, compared to the use of FIB-4 alone (48% vs. 26%, p<0.001), missing the identification of only 4.7% of deaths. The sequential use of FIB-4 and DD represents a comprehensive strategy to identify high-risk COVID-19 patients at hospital admission, potentially minimizing unnecessary DD assessments in patients initially classified by FIB-4 as low-risk for adverse outcomes.

Annals of HepatologyVol. 29
Universidade Federal do Rio de Janeiro (BR), D’Or Institute for Research and Education (BR), Centro Universitário de Barra Mansa (BR)
Openalex Percentile: Top 72%
COVID-19 Clinical Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.